Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis

Meletta, Romana; Herde, Adrienne Müller; Dennler, Patrick; Fischer, Eliane; Schibli, Roger; Krämer, Stefanie-Dorothea

doi:10.1186/s13550-015-0157-4

Cited by 37 publications

(51 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, if the ongoing therapeutical clinical trial with CD80/CD86 targeting CAR-T cells turns out successful, nuclear imaging could aid in patient selection for this treatment approach (ClinicalTrials.gov 2019). Meletta et al investigated in vivo tumor targeting of 111 In-labeled belatacept (Meletta et al 2016). This tracer, a fusion protein consisting of a human IgG1 Fc fragment linked to the extracellular domain of CTLA-4, showed higher uptake in CD80 + /CD86 + Raji tumors (a Burkitt's lymphoma) compared to uptake in double negative NCI-H69 tumors.…”

Section: Ctla-4 Imagingmentioning

confidence: 99%

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Wierstra

Sandker

Aarntzen

et al. 2019

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Immunotherapy with checkpoint inhibitors demonstrates impressive improvements in the treatment of several types of cancer. Unfortunately, not all patients respond to therapy while severe immune-related adverse effects are prevalent. Currently, patient stratification is based on immunotherapy marker expression through immunohistochemical analysis on biopsied material. However, expression can be heterogeneous within and between tumor lesions, amplifying the sampling limitations of biopsies. Analysis of immunotherapy target expression by noninvasive quantitative molecular imaging with PET or SPECT may overcome this issue. In this review, an overview of tracers that have been developed for preclinical and clinical imaging of key immunotherapy targets, such as programmed cell death-1, programmed cell death ligand-1, IDO1 and cytotoxic T lymphocyteassociated antigen-4 is presented. We discuss important aspects to consider when developing such tracers and outline the future perspectives of molecular imaging of immunotherapy markers.

show abstract

Section: Ctla-4 Imagingmentioning

confidence: 99%

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Wierstra

Sandker

Aarntzen

et al. 2019

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…Other methodologies reported in the literature [45,46], for Indium-111 complexation, show some disadvantages such as lengthy and laborious of labeling procedure and higher radiation exposure. Our 99m Tc labeling protocol enables an easy, fast and reliable alternative to prepare radiolabeled micelles for imaging proposes.…”

Section: Discussionmentioning

confidence: 99%

Synthesis, characterization and radiolabeling of polymeric nano-micelles as a platform for tumor delivering

Oda

Fernandes

Lopes

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The use of nanoparticles for diagnostic approaches leads to higher accumulation in the targeting tissue promoting a better signal-to-noise ratio and consequently, early tumor detection through scintigraphic techniques. Such approaches have inherent advantages, including the possibility of association with a variety of gamma-emitting radionuclides available, among them, Tecnethium–99 m (99mTc). 99mTc is readily conjugated with nanoparticles using chelating agents, such as diethylenetriaminepentaacetic acid (DTPA). Leveraging this approach, we synthesized polymeric micelles (PM) consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-mPEG2000) functionalized with DTPA for radiolabeling with 99mTc. Micelles made up of DSPE-mPEG2000 and DSPE-PEG2000-DTPA had a mean diameter of ~10 nm, as measured by DLS and SAXS techniques, and a zeta potential of −2.7 ± 1.1 mV. Radiolabeled micelles exhibited high radiochemical yields and stability. In vivo assays indicated long blood circulation time (456.3 min). High uptake in liver, spleen and kidneys was observed in the biodistribution and imaging studies on healthy and tumor-bearing mice. In addition, a high tumor-to-muscle ratio was detected, which increased over time, showing accumulation of the PM in the tumor region. These findings indicate that this system is a promising platform for simultaneous delivery of therapeutic agents and diagnostic probes.

show abstract

“…13 We have developed a pharmacokinetic model of FDG applicable to premature infants and small children (<5-year old), which may be used to generate model-derived time-integrated activity coefficients and absorbed dose calculations for these patients. 18 …”

Section: Pharmacokinetic Modelingmentioning

confidence: 99%

Dose Estimation in Pediatric Nuclear Medicine

Fahey

Goodkind

Plyku

et al. 2017

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

The practice of nuclear medicine in children is well established for imaging practically all physiologic systems but particularly in the fields of oncology, neurology, urology, and orthopedics. Pediatric nuclear medicine yields images of physiologic and molecular processes that can provide essential diagnostic information to the clinician. However, nuclear medicine involves the administration of radiopharmaceuticals that expose the patient to ionizing radiation and children are thought to be at a higher risk for adverse effects from radiation exposure than adults. Therefore it may be considered prudent to take extra care to optimize the radiation dose associated with pediatric nuclear medicine. This requires a solid understanding of the dosimetry associated with the administration of radiopharmaceuticals in children. Models for estimating the internal radiation dose from radiopharmaceuticals have been developed by the Medical Internal Radiation Dosimetry Committee of the Society of Nuclear Medicine and Molecular Imaging and other groups. But to use these models accurately in children, better pharmacokinetic data for the radiopharmaceuticals and anatomical models specifically for children need to be developed. The use of CT in the context of hybrid imaging has also increased significantly in the past 15 years, and thus CT dosimetry as it applies to children needs to be better understood. The concept of effective dose has been used to compare different practices involving radiation on a dosimetric level, but this approach may not be appropriate when applied to a population of children of different ages as the radiosensitivity weights utilized in the calculation of effective dose are not specific to children and may vary as a function of age on an organ-by-organ bias. As these gaps in knowledge of dosimetry and radiation risk as they apply to children are filled, more accurate models can be developed that allow for better approaches to dose optimization. In turn, this will lead to an overall improvement in the practice of pediatric nuclear medicine by providing excellent diagnostic image quality at the lowest radiation dose possible.

show abstract

Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis

Cited by 37 publications

References 29 publications

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Synthesis, characterization and radiolabeling of polymeric nano-micelles as a platform for tumor delivering

Dose Estimation in Pediatric Nuclear Medicine

Contact Info

Product

Resources

About